Mode
Text Size
Log in / Sign up

EQ-5D Utility Values and Health Related Quality of LifeUnderstanding Quality of Life for Patients Living With Head and Neck Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
The meta-analysis establishes EQ-5D utility scores of 0.79 for head and neck cancer patients to aid in cost-utility modeling.

This meta-analysis provides a comprehensive evaluation of health-related quality of life (HRQoL) and health state utility values (HSUV) for patients diagnosed with head and neck cancer. By aggregating data from a large cohort of 7,403 patients, the study aims to establish baseline metrics for clinical assessment and health economic modeling. The primary outcomes measured include EQ-5D utility scores and EQ-VAS scores, which are standard instruments for quantifying the impact of disease and treatment on daily life.

The analysis revealed a pooled EQ-5D utility score of 0.79 (95% CI: 0.75-0.83). This metric is critical for healthcare administrators and clinicians when calculating Quality-Adjusted Life Years (QALYs) to determine the cost-effectiveness of various therapeutic interventions. The corresponding EQ-VAS score was recorded at 69.36 (95% CI: 65.71-73.01), providing a subjective measure of the patients' perceived health status.

Comparative analysis between different measurement instruments showed that the EQ-5D-5L version yielded higher utility values (0.82) compared to the EQ-5D-3L version (0.76). This distinction is important for clinical researchers selecting standardized tools for longitudinal tracking. Furthermore, the study identified significant variations based on tumor site; for instance, patients with nasopharyngeal cancer reported higher utility values (0.85) than those with oral cancer (0.73).

Despite the large sample size, the study noted extreme heterogeneity in the data (I = 96.4% to 97.1%). This high level of variance suggests that individual patient experiences and local treatment protocols significantly influence HRQoL outcomes. Clinicians should interpret these results as macro-level reference estimates rather than fixed targets for individual patient expectations. From a clinical perspective, these findings are highly relevant for survivorship care planning. By understanding the baseline utility values, oncology teams can better tailor supportive care to address the specific functional limitations associated with different primary tumor sites. The data also serves as a foundational component for health technology assessments, helping to justify the allocation of resources for rehabilitative services.

In conclusion, while the heterogeneity underscores the diversity of the patient experience, the meta-analysis provides a robust statistical framework for evaluating the burden of disease. These utility values are essential for both clinical decision-making and the development of evidence-based protocols to improve the long-term quality of life for patients undergoing treatment for these malignancies.

How this fits prior evidence

How this fits prior evidence This meta-analysis provides a baseline for health-related quality of life (HRQoL) in head and neck cancer patients. While it does not directly address the specific risk of chronic rhinosinusitis in nasopharyngeal cancer or the impact of egg consumption on head and neck cancer risk, it provides the utility values (0.85 for nasopharyngeal cancer) that may be used to model the impact of those specific conditions on patient quality of life.

Living with a diagnosis of head and neck cancer involves much more than just medical treatments. It affects how a person feels every day, how they move, and how they interact with the world around them. Doctors use specific tools to measure these feelings, which help them understand the overall quality of life for their patients.

Researchers looked at data from over 7,000 people to find common patterns in how patients feel. They used a standard scoring system to measure health status. The results showed that while many people manage their daily lives, the experience can vary greatly depending on where the cancer started. For example, patients with certain types of cancer reported different scores than those with others.

These scores are important because they help doctors see the full picture of a patient's health. Instead of only looking at test results, doctors can see how a patient's physical and mental well-being is faring. This information helps medical teams create better plans to support patients during and after their treatment. It helps them focus on making life better for the person, not just treating the illness.

One important finding is that different versions of health surveys can give slightly different results. This means that the way a doctor asks about your health can change the data they collect. Because every patient is unique, these numbers are used as a general guide rather than a specific goal for every individual. They provide a broad map of what patients typically experience.

In the future, this information will help hospitals plan better care for survivors. By understanding the common challenges patients face, doctors can offer more specific support for things like nutrition, speech, and emotional health. This helps ensure that every person receives a plan that addresses their specific needs and helps them live as well as possible after their diagnosis.

What this means for you:
These findings help doctors better understand and support the daily quality of life for patients with head and neck cancer.

Study Details

Study typeMeta analysis
Sample sizen = 7,403
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: Head and neck cancer (HNC) and its treatment can substantially impair speech, swallowing, eating, appearance, and social functioning, resulting in persistent reductions in health-related quality of life (HRQoL). Although the EuroQol 5-Dimensions questionnaire (EQ-5D) is widely used to assess generic HRQoL and derive health state utility values (HSUVs), EQ-5D-based evidence in HNC has not been comprehensively synthesized. This study aimed to summarize EQ-5D-based HRQoL and HSUVs in HNC, estimate pooled utility and EQ-VAS scores, explore subgroup differences, and identify predictors of poorer HRQoL. METHODS: A systematic review and meta-analysis was conducted according to PRISMA guidelines and registered in PROSPERO (CRD420261307907). PubMed, EMBASE, Web of Science, Cochrane Library, and Scopus were searched from inception to February 10, 2026. Studies reporting baseline EQ-5D utility values and/or EQ-VAS scores in patients with HNC were included. Random-effects meta-analyses using the DerSimonian-Laird (DL) estimator with the Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment were performed to pool mean scores. Between-study variance (τ) and 95 % prediction intervals (PI) were calculated to capture parameter dispersion. Subgroup analyses were conducted across clinical and methodological vectors. RESULTS: Twenty studies involving 7,403 patients were included. The pooled mean EQ-5D utility score was 0.79 (95 % CI: 0.75-0.83; τ = 0.0011; 95 % PI: 0.72-0.86). The pooled mean EQ-VAS score was 69.36 (95 % CI: 65.71-73.01; τ = 38.4586; 95 % PI: 55.11-83.61). Extreme heterogeneity was observed (I = 96.4 % and 97.1 %, respectively). Utility values were significantly higher in studies utilizing the EQ-5D-5 L than the EQ-5D-3 L version (0.82 vs. 0.76). By tumor subsite, nasopharyngeal cancer showed the highest utility value (0.85, exploratory), whereas oral cancer demonstrated the lowest (0.73). Adjusted multivariable models revealed that advanced stage, high treatment intensity, severe pharyngolaryngeal pain, dysphagia, malnutrition, and older age were robust predictors of poorer HRQoL. CONCLUSIONS: Patients with HNC experience substantial and persistent HRQoL impairment, with meaningful variations driven by tumor subsites and instrument versions. In light of the extreme heterogeneity, these pooled findings establish a macro-level, broad reference estimate rather than a fixed target. These parameters directly inform localized survivorship care planning, health technology evaluations, and cost-utility decision-making modeling in head and neck oncology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.